0000899243-17-010883.txt : 20170425
0000899243-17-010883.hdr.sgml : 20170425
20170425193729
ACCESSION NUMBER: 0000899243-17-010883
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170421
FILED AS OF DATE: 20170425
DATE AS OF CHANGE: 20170425
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dylan-Hyde Tyler
CENTRAL INDEX KEY: 0001682027
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 17782237
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-21
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682027
Dylan-Hyde Tyler
C/O CRISPR THERAPEUTICS AG
BAARERSTRASSE 14
ZUG
V8
CH-6300
SWITZERLAND
0
1
0
0
Chief Legal Officer
Common Shares
2017-04-21
4
S
0
3010
17.0174
D
192017
D
Common Shares
2017-04-24
4
S
0
3522
16.4387
D
188495
D
Common Shares
2017-04-25
4
S
0
4800
16.8729
D
183695
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 to $17.21, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.91, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
/s/ Michael Esposito, attorney-in-fact
2017-04-25